News

Join scPharmaceuticals' KOL Webinar to Learn About FUROSCIX

Join scPharmaceuticals' KOL Webinar to Learn About FUROSCIX

Understanding the Upcoming KOL Webinar Hosted by scPharmaceuticals

scPharmaceuticals Inc. (NASDAQ: SCPH), based in Burlington, Massachusetts, is making strides in the pharmaceutical industry with its focus on innovative therapies designed to enhance patient care while minimizing healthcare costs. The company has announced an exciting Key Opinion Leader (KOL) webinar that aims to shed light on the clinical use of FUROSCIX, especially its application for heart failure patients experiencing fluid overload.

The Focus of the Webinar

This KOL webinar is set to take place at 1:00 PM ET and will feature insights from Dr. Michael Aaronson, MD, who is well-regarded in the field of nephrology. His expertise will provide attendees with a comprehensive understanding of how FUROSCIX is being utilized to manage fluid overload in heart failure patients, as well as its potential applications for those suffering from chronic kidney disease (CKD).

Key Highlights from the Webinar

The presentation will address beneficial strategies for using FUROSCIX in different patient populations, providing significant information for healthcare professionals dedicated to improving treatment protocols. Attendees will also have the opportunity to engage in a live Q&A session, allowing for a deeper dialogue surrounding patient management and clinical practices.

FIUROSCIX: A Critical Advancement

FUROSCIX (furosemide injection) is specifically designed for the treatment of congestion due to fluid overload in adult patients suffering from chronic heart failure. This medication aims to facilitate an easier administration process, enhancing the overall treatment experience for both patients and providers. The impending FDA decision regarding FUROSCIX’s supplemental new drug application (sNDA) to expand its indication for treating fluid overload in CKD patients is a pivotal point for the company.

Exciting Clinical Developments

The FDA has designated March 6, 2025, as the target date for the decision on the application, which indicates scPharmaceuticals’ commitment to expanding the therapeutic application of FUROSCIX. Moreover, the company is also focusing on developing a low-volume autoinjector, which would empower clinicians and patients with additional options for treatment.

About Dr. Michael Aaronson, MD

Dr. Michael Aaronson brings over two decades of nephrology and internal medicine experience to the table, having graduated from the University of Connecticut School of Medicine. Currently, he leads the nephrology and hypertension division at Lincoln Nephrology, where he continues to teach and mentor future practitioners in the field.

Safety and Efficacy of FUROSCIX

While FUROSCIX offers substantial benefits, it is essential to be aware of its contraindications and potential side effects. Some of the notable side effects may include dehydration, electrolytic imbalances, and hearing changes, especially if dosage guidelines are not strictly adhered to. Continuous monitoring is recommended to mitigate risks associated with its use.

About scPharmaceuticals

scPharmaceuticals is pioneering pharmaceutical solutions aiming to transform outpatient care for acute conditions through innovative and cost-effective therapies. The company emphasizes the importance of self-administration, particularly for IV-strength treatments relevant to heart failure and infectious diseases. Their dedicated team is committed to advancing patient care while striving for optimal health outcomes.

Frequently Asked Questions

What is the purpose of the KOL webinar?

The KOL webinar aims to discuss the use of FUROSCIX in managing fluid overload in heart failure and its potential role in treating chronic kidney disease.

Who is speaking at the KOL webinar?

Dr. Michael Aaronson, MD, an experienced nephrologist, will be sharing insights during the webinar.

What is FUROSCIX used for?

FUROSCIX is used for treating congestion due to fluid overload in adult patients with chronic heart failure.

When is the FDA decision regarding FUROSCIX expected?

The FDA is expected to make a decision on the expanded indication of FUROSCIX by March 6, 2025.

What is scPharmaceuticals focusing on for future growth?

scPharmaceuticals is focused on expanding the use of FUROSCIX, developing new treatment options, and enhancing outpatient care solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 304

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 201

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 296

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Impressive Financial Growth for Caris Life Sciences in Q2 2025

Updated Category News Views 262

Caris Life Sciences Achieves Significant Growth in Financial Results Today, Caris Life Sciences, Inc. (NASDAQ: CAI) reported remarkable financial results, highlighting a 81.3% increase in total revenue year-over-year for the second quarter of 2025. This substantial growth showcases the company's resilience and innovative approach in the ever-evolving healthcare landscape....

Continue Reading
What to Expect from Globus Maritime's Upcoming Earnings Report

Updated Category News Views 253

Anticipating Globus Maritime's Earnings Report Globus Maritime (NASDAQ: GLBS) is gearing up to unveil its quarterly earnings report soon, and investors are eager to gain insight into the company’s financial performance. This report will be a crucial indicator of the company's trajectory as it navigates the ever-changing maritime industry. Analyst Expectations for...

Continue Reading
Discover Exciting Savings with Haoqi E-Bikes This Sale

Updated Category News Views 187

Haoqi E-Bikes Launches Exciting Black Friday Sale With a profound appreciation for family and the great outdoors, Haoqi E-Bikes is thrilled to reveal its noteworthy promotion on the highly sought-after Cheetah Dual Battery Full Suspension E-Bike. From an initial launch date, the brand will provide an incredible discount of $1101 on the Cheetah model to promote outdoor...

Continue Reading
3 Unstoppable Dividend Stocks for Income Investors

Updated Category News Views 125

Finding Reliable Dividend Stocks For investors seeking income, stocks that offer stability and dependable dividends are often the preferred choice. It's generally unwise to invest in companies with uncertain futures that might reduce their dividends. Instead, savvy investors focus on resilient dividend stocks that promise steady returns and growth over time. A Dividend...

Continue Reading
Certification Boosts Aviation Capital's Boeing 737-10 Prospects

Updated Category News Views 115

Nothing like a green light from the FAA to put a little extra swagger in an aircraft lessor's step, and that's exactly what's happening with Aviation Capital Group (ACG) and their big bet on Boeing's 737-10. It's like the champagne just got popped! This milestone is no minor hurdle. We're talking about the largest addition to the 737 MAX family finally giving an official...

Continue Reading